avanafil + omeprazole

**Avanafil + omeprazole** is a combination of two small molecule drugs without a unique brand or code name for the combination. **Avanafil** is a phosphodiesterase 5 (PDE5) inhibitor used for the treatment of erectile dysfunction, acting by increasing cyclic guanosine monophosphate (cGMP) levels in the corpus cavernosum, thus promoting smooth muscle relaxation and increased blood flow. **Omeprazole** is a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease and peptic ulcer disease, working by inhibiting the gastric hydrogen-potassium ATPase pump in parietal cells, thereby reducing gastric acid secretion. No clinical indication or approved use exists for the fixed combination of avanafil and omeprazole, but interaction studies show that avanafil (a weak inhibitor of CYP2C19) can increase the plasma exposure (AUC and Cmax) of omeprazole (a CYP2C19 substrate) by a minor degree[1][3].